Elanco Animal Health (NYSE:ELAN) Issues FY25 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.80-$0.86 for the period, compared to the consensus earnings per share estimate of $0.89. The company issued revenue guidance of $4.445-$4.510 billion, compared to the consensus revenue estimate of $4.52 billion. Elanco Animal Health also updated its Q1 guidance to $0.29-$0.34 EPS.

Elanco Animal Health Stock Up 1.0 %

ELAN opened at $11.14 on Tuesday. Elanco Animal Health has a 12 month low of $10.77 and a 12 month high of $18.80. The company has a 50 day moving average of $11.78 and a 200 day moving average of $13.09. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a market cap of $5.50 billion, a PE ratio of 27.84, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the previous year, the firm earned $0.08 EPS. The firm’s quarterly revenue was down 1.4% compared to the same quarter last year. On average, sell-side analysts expect that Elanco Animal Health will post 0.91 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ELAN shares. Morgan Stanley cut their price objective on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a report on Wednesday, January 29th. Leerink Partners initiated coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price for the company. Stifel Nicolaus decreased their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday. UBS Group started coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Hold” and an average target price of $16.00.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.